Bios -
Use of Surrogate Markers in Monitoring Disease Modifying Therapy in Multiple Sclerosis
 

J. Theodore Phillips, Jr., MD, PhD
Multiple Sclerosis Center at Texas Neurology, Baylor University Medical Center

Dr. Ted Phillips is a graduate of the University of Texas at Austin with special honors in chemistry, and received MD and PhD (Immunology) degrees and Neurology Residency training from the University of Texas Southwestern Medical Center at Dallas. He is director of the Multiple Sclerosis Center at Texas Neurology in Dallas, and serves as a Clinical Associate Professor of Neurology at the University of Texas Southwestern Medical Center and Attending Neurologist at Baylor University Medical Center in Dallas. He is a principal developer of a national registry for MS (MSTRAC), and is a principal investigator in several ongoing clinical treatment trials in MS.

Mariko Kita, MD
Virginia Mason Medical Center, Seattle

Dr. Kita attended medical school at the Northwestern University School of Medicine, her residency in neurology at the Hospital of the University of Pennslyvania, internship in internal medicine at Northwestern Memorial Hospital, and a fellowship in neuroimmunology at Mt. Zion Multiple Sclerosis Center, University of California School of Medicine.

Dr. Kita is currently Director of the Virginia Mason Multiple Sclerosis Center and is board certified by the American Board of Psychiatry and Neurology.

Norman J. Kachuck, MD
University of Southern California School of Medicine

Norman J. Kachuck, MD, is an associate professor of clinical neurology, co-director of the neuroimmunology service of the department of neurology, and director of the USC Multiple Sclerosis Research Group. He earned his MD and completed his training at USC. He also holds a BA in musical composition and performance from UC San Diego.

Dr. Kachuck's clinical interests include multiple sclerosis, immunomodulation, and the nervous system. He is the director of the MS Comprehensive Care Center at USC University Hospital and is involved in clinical trials with new MS medications .